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Abstract Hepatitis C virus (HCV) infection is a serious
health problem leading to cirrhosis, liver failure and
hepatocellular carcinoma. The recent introduction of tela-
previr, which was approved in November 2011, in com-
bination with peg-interferon and ribavirin is expected to
markedly improve the eradication rate of the virus. How-
ever, side effects of triple therapy may be severe. In a phase
three III clinical trial, 2250 mg of telaprevir, which is the
same dosage used in clinical trials in Western countries,
was given to Japanese patients. As this dosage is consid-
ered to be relatively high for Japanese patients, who typi-
cally have lower weight than patients in Western countries,
reduction of telaprevir is recommended in the 2012 revi-
sion of the guidelines established by the Study Group for
the Standardization of Treatment of Viral Hepatitis
Including Cirrhosis published by the Ministry of Health,
Labour and Welfare of Japan. Other protease inhibitors
with fewer side effects are now in clinical trials in Japan.
Alternatively, treatment of patients with combination of
direct acting antivirals without interferon has been repor-
ted. In this review we summarize current treatment options
in Japan and discuss how we treat patients with chronic
HCV infection.
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Abbreviations
HCV Hepatitis C virus
DAAs Direct acting anti-virals
SVR Sustained virological response
RVR Rapid virological response
Introduction
At least 1.5 million people in Japan and more than 200
million people worldwide are chronically infected with
the hepatitis C virus [1, 2]. Due to an aging patient
population, the health burden of chronic HCV infection in
Japan is expected to increase over the next several dec-
ades [3]. Chronic infection develops in 60–80 % of
symptomatic patients, leading to higher risk of cirrhosis,
hepatocellular carcinoma, and end-stage liver disease.
Chronic HCV infection is also one of the primary indi-
cations for liver transplantation [3], and ultimately 5–7 %
of patients die from complications related to HCV
infection [4–7].
The goal of HCV therapy is successful eradication of the
virus and resolution of liver disease. Success is defined as
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the absence of detectable virus 24 weeks following the
end of treatment. In some patients, the virus becomes
undetectable by the end of treatment (end of treatment
response) but then rebounds in the absence of therapy
(relapse or transient response). Viral breakthrough occurs
when the virus rebounds during the course of therapy. In
non-responders, the virus remains detectable throughout
therapy.
Therapy for chronic HCV infection
Hepatitis C virus genotypes vary by region and suscepti-
bility to interferon treatment [8]. Genotype 1 is the most
common genotype worldwide and in Japan [8]. Weekly
injections of pegylated interferon (peg-interferon) and
daily oral administration of ribavirin constitute the standard
therapy for genotype 1 chronic HCV [9]. However, com-
bination therapy is costly and poorly tolerated, requires
long-term treatment (48 weeks), and is successful in only
42–52 % of patients [10–12].
The success rate of HCV therapy in Japan is expected
to improve greatly following the November 2011
approval of telaprevir (VX-950/MP-424; Incivek; Vertex
Pharmaceuticals, Inc., Cambridge, MA, USA), the first in
a class of new direct acting antiviral (DAA) drugs.
Teleprevir and a related drug, boceprevir (Victrelis), were
also recently approved for treatment of genotype 1 in the
US, Canada, and the European Union. While boceprevir
is not approved for use in Japan, a meta-analysis found no
difference in outcomes between the two drugs, except for
slightly higher efficacy among prior relapsers using tela-
previr [13].
Telaprevir and direct acting antiviral drugs
DAAs act by specifically inhibiting essential viral targets.
Telaprevir is an NS3/4 serine protease inhibitor that
mimics the carboxy-terminal region of the NS3 protease
and binds slowly and tightly to the protease [14]. The
NS3-4A protein is also an attractive target due to its
additional role in degrading immune signaling molecules
[15]. Consequently, targeting NS3-4A may not only
disrupt viral replication but may also help to restore
innate antiviral responses [16, 17]. However, treatment
with telaprevir alone often results in a rapid decline in
viral load followed by viral breakthrough due to rapid
selection for resistance mutations [18, 19]. Triple therapy
with peg-interferon, ribavirin, and telaprevir appears to
be required to suppress viral breakthrough and achieve
SVR [20].
Telaprevir clinical trials outside of Japan
Phase II studies
Several phase II and III clinical trials have established the
safety and efficacy of telaprevir in the treatment of HCV
genotype 1 (Table 1). The PROVE I [20] and PROVE II
[21] phase II studies showed SVR rates significantly higher
for triple therapy compared to the standard of care (61 vs.
41 %, 69 vs. 46 %, respectively) after 12 weeks of triple
therapy followed by another 12 weeks of peg-interferon
plus ribavirin combination therapy. Both studies found that
reducing the length of peg-interferon and ribavirin to
12 weeks erased the advantage of triple therapy over
standard therapy, and PROVE II revealed that ribavirin is
required to suppress viral breakthrough [20, 21]. PROVE
III examined the efficacy of triple therapy in patients who
failed to achieve SVR during prior interferon therapy and
reported improved SVR rates among patients with prior
nonresponse (39 %), relapse (69 %), or viral breakthrough
(57 %) [22].
Phase III studies
The phase III ADVANCE study compared duration of
telaprevir therapy in treatment-naive patients using three
treatment arms, a control peg-interferon plus ribavirin
group and 8 and 12 week telaprevir triple therapy groups
followed by response-guided peg-interferon plus ribavirin
combination therapy [23] (Table 1). SVR rates were 69 %
for the 8 week telaprevir treatment and 75 % for the
12 week telaprevir treatment, compared to 44 % for stan-
dard peg-interferon plus ribavirin combination therapy.
The phase III REALISE study assessed response to triple
therapy in patients with prior treatment failure [24]. Prior
relapsers, partial responders, and null responders were
randomized to a 48 week peg-interferon plus ribavirin
control group or to 48 week triple therapy groups with
12 weeks of telaprevir with or without a 4 week peg-
interferon plus ribavirin lead-in phase. SVR rates in the
triple therapy group were 66 % with the lead-in phase and
64 % without it, compared to only 17 % in the control
group. When analyzed by response to prior treatment, prior
relapsers showed the strongest improvement in SVR rates,
but triple therapy also appears to benefit prior null and
partial responders as well [24–26]. Based on these studies,
the U.S. Food and Drug Administration (FDA) approved
response-guided therapy (RGT) for prior relapsers who
achieved extended rapid virological response (eRVR) [27].
This allows prior relapsers to discontinue all treatment after
24 weeks if HCV RNA is undetectable at weeks 4 and 12.
In Japan, duration of triple therapy is 24 weeks without
regard for response to prior treatment.
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Table 1 Summary of telaprevir clinical trials
Study Design Results
PROVE I
McHutchison et al. [20]
Phase II; N = 233
T12PR24: 12 week TVR ? 24 week PR
T12P48: 12 week TVR ? 24 week PR






Hezode et al. [21]
Phase II; N = 334
T12PR24: 12 week TVR ? 24 week PR





McHutchison et al. [22]
Phase II; N = 465
Patients with prior PR treatment failure
T12PR24: 12 week TVR ? 24 week PR
T24PR48: 12 week TVR ? 24 week PR
T24P24: 12 week TVR ? 24 week PR







Jacobson et al. [23]
Phase III double-blind; N = 1088
Treatment-naı¨ve patients
T8PR: 8 week TVR ? 24 or 48 week PR RGT
T12PR: 12 week TVR ? 24 or 48 week PR RGT






Sherman et al. [55]
Phase III open-label; N = 540
Treatment-naı¨ve patients
T12PR24: 12 week TVR ? 24 or 48 week PR RTG





Zeuzem et al. [24]
Phase III; N = 662
Patients with prior PR treatment failure
T12PR48: 8 week TVR ? 48 week PR
Lead-in T12PR48: 4 week PR ? 8 week TVR ? 48 week PR
PR48: 12 week placebo ? 48 week PR
SVR by treatment
T12P48: 64 %
Lead-in T12P48: 66 %
PR48: 17 %
SVR by prior history
Relapsers: 83–88 %
Partial responders: 54–58 %
Non-responders: 29–33 %
Yamada et al. [32] Phase Ib; N = 10
Treatment-naive Japanese patients
TVR monotherapy: 12 week
ETR: 10 %
Ozeki et al. [19] Phase IIa; N = 4; single-arm, open label
Older female Japanese patients with prior PR treatment failure
TVR monotherapy: 24 week ? off-study PR
SVR (off-study): 100 %
Toyota et al. [33] Phase II; N = 15; single-arm, open-label
Treatment-naive Japanese patients
TVR monotherapy: 24 week
SVR: 7 %
Kumada et al. [28] Phase III; N = 189
Treatment-naı¨ve Japanese patients
TR12P24: 12 week TVR ? 12 week PR
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Clinical trials of telaprevir in Japan
Triple therapy in treatment-naive patients
Although Asians are under-represented in the above studies
(1–2 %), several phase II and III clinical trials have also
been performed in Japan (Table 1). In Kumada et al. [28],
126 patients were randomly assigned to 12 weeks of tela-
previr triple therapy followed by 12 weeks of combination
therapy, and 63 patients were assigned to 48 weeks of
combination therapy. Early viral dynamics varied greatly
between the two groups, with more rapid and extensive loss
of HCV RNA and a significantly higher rate of SVR in the
triple therapy group (73.0 vs. 49.2 %). Rates of viral
breakthrough and relapse did not differ between the treat-
ment groups. However, patients who underwent triple
therapy experienced a significantly higher incidence of side
effects during the telaprevir phase of the treatment.
Because HCV patients in Japan tend to be more than
10 years older than patients in Western countries and
include a higher proportion of women, ribavirin-induced
anemia is of particular concern [29]. Moderate or severe
anemia developed in 38.1 % of patients in the triple ther-
apy group compared to 17.5 % in the combination therapy
group [30]. The ribavirin dose was adjusted accordingly,
resulting in a lower total ribavirin dose in the triple therapy
group. However, ribavirin dose reduction did not signifi-
cantly impact treatment efficacy. Skin disorders were about
twice as common in triple therapy patients (46.8 vs.
23.8 %), and severe skin lesions were only observed in this
group. Due to the higher SVR rate and shorter duration of
triple therapy, the study authors recommend triple therapy
over combination therapy for treatment of HCV genotype 1
in Japan but stress the need for careful monitoring of
hemoglobin levels and close coordination with a
dermatologist.
Triple therapy in patients with prior treatment failure
In a second phase III clinical trial in Japan, Hayashi et al.
[31] examined the safety and efficacy of triple therapy for
difficult-to-treat patients who either relapsed (109) or failed
to respond to prior interferon therapy (32). As in the pre-
vious studies, patients were treated to 12 weeks of triple
therapy followed by 12 weeks of combination therapy.
SVR rates were 88.1 % for prior relapsers and 34.4 % for
prior non-responders. Adverse events were common but
moderate. 82 % of patients experienced rash or other skin
disorders, mainly during the telaprevir phase, and nearly all
(98.6 %) patients required ribavirin dose reduction for
anemia, although ribavirin dose reduction had no effect on
SVR rate down to about 20 % of the planned dose. Tela-
previr was discontinued in 21.3 % of patients, and all drugs
were discontinued in 16.3 % of patients. SVR rates in prior
relapsers were significantly higher among men than women
(93.9 vs. 79.1 %), but there was no difference among prior
non-responders. Rates of viral breakthrough (18.8 %) and
relapse (40.6 %) were significantly higher among prior
non-responders and were more common after completion
of the telaprevir phase, suggesting that extension of tela-
previr therapy past 12 weeks or continuation of combina-
tion therapy past 24 weeks may improve response for prior
non-responders. The study authors recommend weekly
hemoglobin monitoring and note that even sharp reductions
in ribavirin dose my allow therapy to continue without
adversely affecting outcome.
Side effects of telaprevir in clinical trials in Japan
An early phase Ib study was conducted in Japan to examine
the safety, tolerability, and antiviral profile of telaprevir
monotherapy over 12 weeks in 10 treatment-naive patients
with high viral loads of genotype 1b [32]. Telaprevir was
well tolerated and no serious adverse events occurred, but
80 % of patients developed a rash and 70 % experienced
anemia. Telaprevir monotherapy demonstrated potent
antiviral activity, with HCV RNA levels decreasing by 2.3
log10 by 16 h and by 5.2 log10 after 2 weeks. HCV RNA
dropped to the limit of detection or became undetectable in
all patients during the course of therapy, but only one
patient achieved an end-of-treatment response. Viral
breakthrough occurred in 8 patients, mainly due to Ala156
mutation. However, resistance mutants reverted to wild
type during the 24 week follow-up period.
Table 1 continued
Study Design Results
Hayashi et al. [31] Phase III; N = 141
Patients with prior PR treatment failure
TR12P24: 12 week TVR ? 12 week PR




TVR telaprevir, PR peg-interferon plus ribavirin combination therapy, RGT response-guided therapy—24 week PR if undetectable HCV RNA at
weeks 4 and 12 (eRVR); otherwise 48 week PR, ETR end-of-treatment response
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Another study examined safety and efficacy of telaprevir
monotherapy over a longer duration of 24 weeks with a
larger number of patients and a greater range of viral loads
[33]. The only patient who achieved SVR also had the
lowest baseline viral load (3.55 log10 IU/ml), but three
other patients were able to achieve an end-of-treatment
response. HCV RNA levels decreased rapidly (average -5
log10 IU/ml), and HCV RNA became undetectable in 5
patients within 8 weeks. 10 out of 15 patients (66 %) dis-
continued the drug due to viral breakthrough, adverse
events, or other causes. Incidence of adverse events was
high (14/15 patients) and 7 out of 15 patients (47 %)
developed anemia, but most incidences were mild to
moderate, and anemia did not lead to discontinuation of
therapy. T54A and A156V variants were the most common
and were not detectable at earlier time points. Secondary
substitutions at V158I and I132L were also observed.
SVR rates tend to be lower among women than men
over 50 in Japan (53 vs. 22 %), and dose reductions and
discontinuation of treatment in standard therapy are high in
this group [34]. Ozeki et al. [19] examined 24 weeks of
telaprevir monotherapy in a group of four older female
patients predicted to be difficult to treat due to age, sex, and
Core70 and ISDR substitutions. All patients required tela-
previr dose reduction due to anemia but did not require
discontinuation. Resistance variants were detected in three
patients, and two patients experienced viral breakthrough.
Additional substitutions and variants emerged as therapy
progressed. However, at the end of the telaprevir admin-
istration, all four patients were given at least 48 weeks of
standard therapy, and all patients were able to achieve
SVR. Although this approach results in longer duration of
therapy, it avoids the need for simultaneous administration
of the three drugs and takes advantage of the fact that
resistance mutants selected during telaprevir therapy often
have reduced fitness compared to the wild type and are
more susceptible to standard therapy.
Telaprevir antiviral resistance
Pre-existence of resistance mutations and selection for
resistance may be an inevitable consequence of DAA
therapy [35]. The high replication rate of HCV high (1012
viruses per day) coupled with the low fidelity of HCV
polymerase results in a high mutation rate (10-3–10-5 per
day) and the presence of viral quasispecies. Single and
double substitutions from the consensus sequence are
expected to exist at low frequency prior to therapy. The
relative proportion of these variants increases rapidly in
the viral population as the wild-type virus is eradicated.
De novo mutations appear to play only a minor role in
the emergence of resistance mutations, suggesting that a
genetic barrier of three to four mutations might be suffi-
cient to reduce selection based on pre-existing mutants.
At the same time, mutations conferring resistance often have
reduced fitness and may require compensatory mutations in
order to compete with wild-type viruses. Nonetheless, HCV
sub-genotypes vary substantially in sequence, and some are
likely to have a reduced genetic barrier against certain
DAAs. For example, viral genotypes 1a and 1b already have
different genetic barriers to telaprevir resistance; amino acid
substitution of amino acid 155 requires only one nucleotide
change in genotype 1a, whereas genotype 1b requires two
nucleotide substitutions [36, 37]. Resistance substitutions at
six major sites within the NS3 HCV protease have been
reported, including at amino acids 36, 54, 155, 156, 168, and
170, and some substitutions are known to act synergistically
[35]. At least 50 direct-acting antiviral drugs are at some
stage of development, but these belong to a small number of
distinct drug classes, increasing the risk of cross-resistance.
Although wild-type strains are typically restored following
removal of the drug due to viral breakthrough, prior treat-
ment experience with DAAs, especially in high-risk sub-
populations such as injection drug users, may increase the
risk of transferring partially resistant strains during new
infections.
Patient selection and predictive factors for triple
therapy
Telaprevir triple therapy is an extension of peg-interferon
plus ribavirin combination therapy. Therefore, factors that
predict the outcome of combination therapy might also
help to predict outcome of triple therapy. Age, fibrosis,
obesity, hepatic steatosis [38], LDL cholesterol, gamma-
GTP [39], insulin resistance [40], baseline viral titer
[38, 41], and IL28B SNP genotype [42–44] are known to
affect response to combination therapy. HCV genotype
[41] and genetic variants within the viral genome, includ-
ing amino acid substitutions at positions 70 (Core70) and
91 (Core91) of the HCV core protein and substitutions
within the NS5A interferon sensitivity determining region
(ISDR) [45, 46], are also thought to influence response to
combination therapy. Akuta et al. [47] reported that Core70
substitution and partial response to prior therapy were
significant predictors of SVR for triple therapy, and partial
response and alpha-fetoprotein levels were significant
predictors of end-of-treatment response. Chayama et al.
[26] reported that IL28B SNP genotype, rapid virological
response (RVR), and response to prior therapy were pre-
dictive of outcome of triple therapy. Prior relapsers
achieved high levels of SVR (93 %), whereas patients who
failed to respond to combination therapy were also less
likely to respond to triple therapy. ITPA SNP genotype did
J Gastroenterol (2013) 48:1–12 5
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not influence outcome of therapy, but patients with the
anemia-susceptible ITPA SNP rs1127354 genotype typi-
cally required ribavirin dose reduction earlier than patients
with other genotypes. Predictive factors for SVR identified
during the ADVANCE phase III clinical trial include race,
viral load, IL28B, RVR, and stage of fibrosis [48]. IL28B
and on-treatment factors such as RVR appear to remain
important predictors for response to triple therapy and may
aid in patient selection and determination of treatment
duration [48].
2012 guidelines for treatment of patients
with chronic hepatitis C
Two guidelines for treatment of chronic HCV are available
in Japan, both providing recommendations for patient
selection for telaprevir triple therapy. Triple therapy in
Japan consists of 12 weeks of telaprevir (Telavic) in
combination with 24 weeks of dual peg-interferon a 2b
(Peg-Intron) and 24 weeks of ribavirin (Rebetol).
Study Group for the Standardization of Treatment
of Viral Hepatitis Including Cirrhosis: 2012 Guideline
on Therapy for Chronic Hepatitis C
The following are the most recent guidelines from the
Study Group for the Standardization of Treatment of Viral
Hepatitis Including Cirrhosis published by the Ministry of
Health, Labour and Welfare of Japan (Tables 2, 3, 4, 5, 6).
The recommended course of treatment differs depending
on HCV genotype, viral titer, and prior history of interferon
treatment. Patients with high viral load ([5.0 log IU/ml) of
genotype 1 are considered difficult to treat and are rec-
ommended for triple therapy in both interferon treatment-
naive and treatment-experienced patients (Tables 2, 3). In
this group of patients, IL28B SNP genotype, HCV Core70
and ISDR substitutions are strong predictors of treatment
outcome and may be used to determine the starting therapy.
Patients with rs8099917 TT genotype are recommended for
triple therapy. If telaprevir is contraindicated due to age,
gender, or hemoglobin levels, peg-interferon plus ribavirin
may be used instead (Table 4). However, combination
therapy alone without telaprevir is not recommended for
patients with rs8099917 TG/GG genotype, Core70 mutant,
and wild type ISDR (0–1 substitutions) due to poor
response to combination therapy in these patients
(Table 4). For treatment-naive patients with low viral loads
of either genotype 1 or genotype 2, the recommended
treatment is 24–48 weeks of peg-interferon a 2a (Pegasys)
(Table 1). Recommended treatment for patients with high
viral load of genotype 2 is 24 weeks of dual therapy with
ribavirin and either peg-interferon a 2b or interferon b
(Feron). In the case of adverse drug reactions, such as
depression, or in the case of increased risk of adverse drug
reactions due to age, interferon b plus ribavirin should be
Table 2 Study Group for the
Standardization of Treatment of
Viral Hepatitis Including
Cirrhosis: 2012 guidelines for
chronic hepatitis C therapy for
treatment-naive patients
Genotype 1 Genotype 2
High viral load Peg-IFN a 2b: Peg-Intron (24 weeks) Peg-IFN a 2b: Peg-Intron
C5.0 log IU/mL ?Ribavirin: Rebetol (24 weeks) ?Ribavirin: Rebetol (24 weeks)
C300 fmol/L ?Telaprevir: Telavic (12 weeks) IFN b: Feron
C1 Meq/mL ?Ribavirin: Rebetol (24 weeks)
Low viral load IFN (24 weeks) IFN (8–24 weeks)
\5.0 log IU/mL Peg-IFN a 2a: Pegasys (24–48 weeks) Peg-IFN a 2a: Pegasys (24–48 weeks)
\300 fmol/L
\1 Meq/mL
Table 3 Study Group for the
Standardization of Treatment of
Viral Hepatitis Including
Cirrhosis: 2012 guidelines for
chronic hepatitis C therapy for
previously treated patients
Genotype 1 Genotype 2
High viral load
C5.0 Log IU/mL
C300 fmol/L Peg-IFN a 2b ? Ribavirin (24 weeks) Peg-IFN a 2b ? Ribavirin (36 weeks)
OR
C1 Meq/mL ?Telaprevir (12 weeks) combined therapy Peg-IFN a 2a ? Ribavirin (36 weeks)
OR
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considered for patients, regardless of genotype 1 or 2.
Previously treated patients with genotype 1 should be
treated with triple therapy, consisting of 12 weeks of
telaprevir and 24 weeks of peg-interferon a 2b and riba-
virin regardless of viral load (Table 3). Patients with
genotype 2 should be given 36 weeks of dual therapy with
ribavirin and either peg-interferon a 2a/b or interferon b
(Table 3).
Telaprevir triple therapy is associated with an increased
risk of anemia, skin lesions, and other side effects compared
to peg-interferon plus ribavirin dual therapy, especially
among females and older patients [20, 26]. Initial dosages
should be determined based on the patient’s age, weight,
and expected tolerability. However, for female patients with
baseline hemoglobin levels between 13 and 14 g/dl or male
patients with baseline hemoglobin levels between 12 and
13 g/dl, ribavirin dosage should be reduced by 200 mg and
telaprevir dosage should be reduced to 1500 mg (Table 5).
Triple therapy is unsafe in patients with baseline hemo-
globin levels \12 g/dl. Hemoglobin levels should be clo-
sely monitored, and in the case of anemia ribavirin, dosage
should be reduced based on both the absolute value of the
hemoglobin levels as well as the amount of the reduction
(Table 6). Triple therapy should be conducted in coopera-
tion with a dermatologist to manage the high risk of
potentially serious skin problems, including Stevens–
Johnson syndrome and drug-induced hypersensitivity syn-
drome. Use of all three drugs should immediately cease in
the event of serious skin problems. In the event of cutaneous
symptoms, adequate treatment should begin early in con-
sultation with a dermatologist. Benefits and risks of
administration of oral steroids or other drugs should be
Table 4 Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis: pretreatment indicators for triple therapy
Indications for therapy involving a host factor (IL28B) and two viral factors (ISDR and Core70) at the start of triple combined therapy
including telaprevir in the initial therapy for the treatment-naive patients with high viral load of genotype 1
1. Telaprevir triple therapy is recommended in patients homozygous for the favorable IL28B SNP allele (e.g., rs8099917 T/T genotype)
because the anticipated effect of the therapy is high. If telaprevir therapy is likely to be difficult in consideration of the patient’s age, gender,
hemoglobin level, or other factor, then peg-interferon a or interferon b plus ribavirin combination therapy should be chosen instead
2. Telaprevir triple therapy may be preferred over interferon plus ribavirin combination therapy in patients with an unfavorable IL28B SNP
genotype (rs8099917 T/G or G/G), wild-type ISDR (0–1 substitutions), and a Core70 mutation, because the effect of interferon plus
ribavirin combination therapy is low in these patients
Table 5 Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis: guidelines for ribavirin and telaprevir dose
reduction based on baseline hemoglobin levels
Baseline hemoglobin (g/dl) Ribavirin Telaprevir
C14.0 Conventional dose Conventional dose (2250 mg)
13.0–14.0 Decrease by 200 mg (females only) Decrease to 1500 mg (females only)
12.0–13.0 Decrease by 200 mg Decrease to 1500 mg
\12.0 Triple therapy unsafe
Initial ribavirin and telaprevir dosages relative to hemoglobin levels are estimated based on the results of clinical trials. Initial dosages should be
determined by a specialist based on the patient’s age, weight, etc
Table 6 Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis: precautions for triple therapy with peg-
interferon a 2b, ribavirin, and telaprevir in case of high viral load of genotype 1
1. Severe anemia occurs more frequently in peg-interferon a 2b plus ribavirin plus telaprevir triple therapy compared to interferon plus
ribavirin combination therapy. Care should be taken to monitor hemoglobin levels, and in case of anemia, ribavirin dosage should be
adjusted based on consideration of both the absolute value of hemoglobin as well as the amount of hemoglobin reduction. Because the risk
of anemia increases with age, peg-interferon a or interferon b plus ribavirin combination therapy is the preferred initial therapy for older
female patients or patients with low hemoglobin levels and high viral loads of genotype 1
2. Peg-interferon a 2b plus ribavirin plus telaprevir triple therapy should be conducted in coordination with a dermatologist because serious
skin problems such as Stevens–Johnson syndrome and drug-induced hypersensitivity syndrome are likely to occur. In the event of severe
skin problems, use of all three drugs should be immediately ceased. If cutaneous symptoms are expressed, adequate treatment should begin
at an early date. Course of treatment should be decided in cooperation with a dermatologist in view of the respective risks and benefits, and
administration of oral steroids should be considered if necessary
3. Some patients experience an increase in uric acid and creatinine levels rise during the first week of peg-interferon a 2b plus ribavirin plus
telaprevir triple therapy. If uric acid levels become aberrant, early administration of a therapeutic agent for hyperuricemia is required
J Gastroenterol (2013) 48:1–12 7
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considered, if necessary. Some patients may also experi-
ence a rapid increase in uric acid levels at the start of
therapy (1–7 days), in which case a therapeutic agent
should be administered early to reduce hyperuricemia.
Japan Society of Hepatology: 2012 guidelines
for treatment of chronic HCV
The 2012 guidelines supported by the Japan Society of
Hepatology (http://www.jsh.or.jp/english/index.html) pro-
vide more specific recommendations for patients with high
viral load of HCV genotype 1 based on factors including
patient age, IL28B SNP genotype, Core70 and ISDR sub-
stitutions, prior treatment history, and stage of fibrosis. The
English version of this guideline will be published soon in
Hepatology Research (2012). Treatment-naive patients with
rs8099917 TT genotype should be given triple therapy, if
possible, but combination therapy may be substituted if
telaprevir is contraindicated (Fig. 1a). Interferon b plus
ribavirin may also be substituted in case of depression.
Therapy should also be postponed in patients with both the
unfavorable IL28B SNP genotype (TG/GG) and Core70
mutation due to the poor expected outcome of therapy. When
IL28B and Core70 data are not available, patients should be
treated with triple therapy or combination therapy, depend-
ing on tolerability and fibrosis stage (Fig. 1b). Therapy may
be postponed in nonelderly patients (B65) with mild fibrosis.
Triple therapy provides a retreatment opportunity for
patients who were unable to eradicate the virus during prior
therapy. However, not all patients show an improved
response, and a patient’s response to the prior therapy should
be used as a guide for treatment selection, if available. Patients
who experienced relapse or partial response are expected to
respond well to therapy and should be administered triple
therapy or combination therapy depending on age and stage of
fibrosis (Fig. 2a). On the other hand, patients who experi-
enced null response during prior therapy should be adminis-
tered triple therapy, if possible; otherwise, treatment should
be postponed, as combination therapy alone is unlikely to be
successful. When treatment history is unknown but IL28B
SNP and Core70 data are available, guidelines for treatment-
naive patients should be followed (Fig. 2a). In the absence of
A IL28B SNP/Core70 substitution data available
B IL28B SNP/Core70 substitution information is unavailable
Fig. 1 Japan Society of Hepatology: 2012 treatment guidelines for
treatment-naive chronic HCV patients with high viral load of
genotype 1. a Patients with the favorable IL28B SNP genotype
(rs8099917 TT) and/or wild type viral core protein amino acid 70
(Core70) should be treated with triple or combination therapy, if
possible, depending on age and fibrosis stage. Patients with both the
unfavorable IL28B SNP genotype (TG/GG) and Core70 substitution
should postpone therapy due to poor expected outcome. b When
IL28B SNP genotype and Core70 substitutions are unavailable,
treatment is determined based on patient age and stage of fibrosis
A Prior treatment history is known
B Prior treatment history is unknown*1
*1 Consider IFN-β + RBV in case of depression
*2 For abnormal ALT levels, consider liver supporng therapy or an extended course of low-dose pegIFN or IFN
*1 If IL28B SNP and core amino acid 70 informaon available, treat using guidelines for treatment-naïve paents
*2 Consider IFN-β + RBV in case of depression
*3 For abnormal ALT levels, consider liver supporng therapy or an extended course of low-dose pegIFN or IFN
Fig. 2 Japan Society of Hepatology: 2012 treatment guidelines for
re-treatment of previously treated chronic HCV patients with high
viral load of genotype 1. a Patients who experienced relapse or partial
response during prior interferon therapy should be treated with triple
therapy or combination therapy, if possible, depending on age. Triple
therapy is recommended for patients who experienced null response
to prior therapy, but if triple therapy is not possible, therapy should be
postponed due to poor expected response to combination therapy in
these patients. b When prior treatment history is unavailable but
IL28B SNP and core amino acid 70 (Core70) information is available,
guidelines for treatment-naive patients should be followed (Fig. 1a).
When both prior treatment history and IL28B SNP and Core70
information are unavailable, triple therapy is recommended for older
patients as well as for younger patients with advanced fibrosis. If
fibrosis is mild, triple therapy for younger patients should be
postponed
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both treatment history and IL28B/Core70 data, patients
should be treated with triple therapy or combination therapy,
depending on tolerability and fibrosis stage (Fig. 2b).
Future therapies
The development, clinical testing, and approval of tela-
previr triple therapy is the culmination of a decades-long
process [49]. At the same time, however, the introduction of
telaprevir and boceprevir represents the first success in a
much broader direct antiviral strategy targeting multiple
facets of the viral life cycle. Future clinical trials involving
triple therapy are likely to lead to further improvements in
SVR rate, shorter duration of therapy, and improved man-
agement of side effects, especially among specific patient
subgroups. Future research will also identify new predictive
factors associated with response to DAA therapy, including
risk of viral breakthrough and adverse events.
A major goal of future clinical research, however, is to
move beyond interferon-based therapy in favor of interferon-
free DAA combination therapies. A number of novel DAAs
are currently undergoing clinical testing (Table 7), and
DAAs are being evaluated in combination with interferon as
well as other DAAs (Table 8). Many other drugs and vac-
cines are currently in some stage of clinical testing
(http://www.hcvadvocate.org/hepatitis/hepC/HCVDrugs_
2012.pdf). Telaprevir and other DAAs under development
are not intended for use in monotherapy due to the low
genetic barrier to resistance. However, combinations of
DAAs with different viral targets and mechanisms of action
should have a higher genetic barrier. For example, in a
chimeric mouse model a protease inhibitor (telaprevir) in
combination with an RNA polymerase inhibitor (MK-0608)
resulted in rapid clearance of HCV RNA without emer-
gence of resistance mutants [50].
Several DAA combination therapies have entered phase
II clinical trials in humans. Safety and efficacy of dual
therapy with daclatasvir (NS5A inhibitor) and asunaprevir
(NS3 protease inhibitor) was examined in two phase II
clinical trials in the US and Japan for difficult-to-treat
genotype 1 patients with null response to prior interferon
therapy [51–53]. The studies differed notably with respect to
sub-genotype; 81 % of patients in the US study had genotype
1a, whereas all patients in the Japanese study had genotype
1b. In the Japanese study, 77 % of patients achieved SVR
(90 % in the sentinel cohort) [52, 53], whereas in the dual
DAA therapy arm of the US study (group A), only 36 % of
Table 7 Direct-acting antiviral
(DAA) drugs in clinical testing
Phase I Phase II Phase III Phase IV
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patients achieved SVR, while the other patients either
relapsed or had viral breakthrough [51]. In the latter study,
the two patients with genotype 1b both achieved SVR. All
patients in group B, in which all patients received peg-
interferon plus ribavirin in addition to daclatasvir and
asunaprevir, achieved SVR at 12 weeks after treatment.
These discrepancies may reflect differences between geno-
types 1a and 1b in the genetic barrier for resistance to this
drug combination [51] and suggest that such treatments may
be more amenable in Japan where genotype 1b is common.
In another phase II dual DAA therapy study, treatment-
naive genotype 1 patients were administered GS-9256, an
NS3 serine protease inhibitor, and tegobuvir (GS-9190), a
non-nucleoside NS5B polymerase inhibitor, with or without
peg-interferon and ribavirin, followed by standard therapy
with peg-interferon plus ribavirin [54]. Only 7 % of patients
receiving dual DAA therapy alone achieved RVR, whereas
RVR rates increased to between 67 and 100 % among
patients who also received peg-interferon and/or ribavirin.
Although promising, these studies suggest that interferon
and ribavirin will continue to be used in future DAA
combination therapies to control viral breakthrough.
Future perspective and conclusion
Although SVR rates still fall far short of 100 %, the recent
introduction of telaprevir to standard peg-interferon plus
ribavirin therapy greatly increases the chance that a patient
with chronic HCV infection will be able to successfully
clear the virus, and it offers a promising retreatment
opportunity for patients who were unable to clear the virus
in previous therapy attempts. Despite the higher SVR rate,
however, triple therapy also further limits patient eligibility
and increases the burden on patients. This issue is of par-
ticular concern in Japan where patients tend to be older
than in Western countries and at greater risk for HCC, as
well as more likely to face complications or treatment
discontinuation due to adverse events.
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